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Abstract 
Background: There is a growing body of literature highlighting the role that wearable and 
mobile remote measurement technology (RMT) can play in measuring symptoms of major 
depressive disorder (MDD). Outcomes assessment typically relies on self-report, which can 
be biased by dysfunctional perceptions and current symptom severity. Predictors of 
depressive relapse include disrupted sleep, reduced sociability, physical activity, changes in 
mood, prosody and cognitive function, which are all amenable to measurement via RMT. This 
study aims to: 1) determine the usability, feasibility and acceptability of RMT; 2) improve and 
refine clinical outcome measurement using RMT to identify current clinical state; 3) determine 
whether RMT can provide information predictive of depressive relapse and other critical 
outcomes.  
Methods: RADAR-MDD is a multi-site prospective cohort study, aiming to recruit 600 
participants with a history of depressive disorder across three sites: London, Amsterdam and 
Barcelona. Participants will be asked to wear a wrist-worn activity tracker and download 
several apps onto their smartphones. These apps will be used to either collect data passively 
from existing smartphone sensors, or to deliver questionnaires, cognitive tasks, and speech 
assessments. The wearable device, smartphone sensors and questionnaires will collect data 
for up to 2-years about participants’ sleep, physical activity, stress, mood, sociability, speech 
patterns, and cognitive function. The primary outcome of interest is MDD relapse, defined via 
the Inventory of Depressive Symptomatology- Self-Report questionnaire (IDS-SR) and the 
World Health Organisation’s self-reported Composite International Diagnostic Interview (CIDI-
SF). 
Discussion: This study aims to provide insight into the early predictors of major depressive 
relapse, measured unobtrusively via RMT. If found to be acceptable to patients and other key 
stakeholders and able to provide clinically useful information predictive of future deterioration, 
RMT has potential to change the way in which depression and other long-term conditions are 
measured and managed.   
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Background 
The last decade has seen an explosion in the capability of monitoring individuals via sensors 
in smartphones or wearable devices, and the range of parameters which can be measured by 
such technologies will continue to grow (1). The development of remote measurement 
technologies (RMT), using these inbuilt sensors to unobtrusively measure human behaviour 
and physiology, combined with active measurement of daily experiences via smartphone 
apps,  is an innovation which could be used to provide real-time information about patients’ 
current clinical state, as well as information potentially predictive of future deterioration (1).  
Major Depressive Disorder (MDD) is associated with a wide range of negative outcomes 
including: premature mortality (2); reduced quality-of-life (3); loss of occupational function (4); 
and is often experienced alongside physical comorbidity (5) and approximately 55% will go on 
to develop chronic depression, characterised by periods of recovery and relapse (6,7). 
Developing interventions which can disrupt the pattern of remission and relapse is of crucial 
importance to maintain sustained periods of recovery (8) . Predictors of depressive relapse 
include disrupted sleep (9), reduced sociability (10), changes in mood  (11), prosody (12) and 
cognition (13), and there is evidence highlighting the impact psychological and 
pharmacological interventions can have on reducing risk of relapse (14,15). Identifying the 
optimal time to deliver a preventative intervention, when these symptoms may be sub-
threshold, context dependent, or too subtle for the individual to recognise, is challenging. 
Symptom recall in patients with depression may also not be accurate, potentially biased by 
current symptom severity and environmental stressors (16,17). This retrospective recall 
cannot capture symptom variability and context reactivity which would allow interventions to 
be administered at a crucial point in the relapse signature.  
RMT may provide a solution to these problems by giving richer, objective characterisation of 
behaviour, cognition, speech and physiology. Data can be collected with excellent temporal 
resolution, including an ability to assess diurnal variation which may be indicative of early 
decline in mood (18). Passive RMT (pRMT) uses sensors in activity monitors and smartphones 
to gather data with no input from the wearer (19), including Global Positioning System (GPS), 
accelerometer, gyroscope, communication logs, ambient noise and light levels and screen 
interactions. Many of these sensors have been used to identify changes in sleep, 
communication and activity patterns associated with depressive episodes (20,21). Prosodic 
speech characteristics, such as speaking rate, pitch, pause duration and energy, collected via 
smartphone microphones, have been used to detect depression with a prediction accuracy of 
81.3% (22). Active RMT (aRMT) uses smartphone apps to deliver validated questionnaires, 
cognitive games, speech tasks or electronic diaries using the experience sampling method 
(ESM) to provide fine-grained understanding of mood changes and stressors in the context of 
daily life (23). aRMT has been used to measure affect, cognitions, thoughts, mood and 
behaviours in real-time, with evidence highlighting the increased validity of this methodology 
in comparison to traditional retrospective reports (24). aRMT assessments of positive and 
negative affect have also been found to be reliably indicative of mood state (25,26) and have 
been associated with MDD symptoms (27). 
 
Despite this growing body of research evidence, there has been limited assessment of the 
utility of multi-parametric RMT in clinical populations (28,29), combining multiple sensors to 
detect signatures potentially useful for predicting outcomes in MDD. This protocol describes 
the clinical study designed to test this utility of RMT. 
 
Patient Involvement in the RADAR-MDD study protocol 
Systematic reviews have identified the barriers and facilitators of RMT uptake (30); service-
user focus groups have identified the outcomes prioritised by service-users, identified 
appropriate methods of measuring these outcomes, and investigated the use of technology to 
measure and manage symptoms (31); surveys and user experience testing have informed the 
selection of devices and development of all user-facing systems to ensure optimal usability 
and functionality. Extensive device-selection procedures combined all acquired knowledge 
from literature reviews, focus groups and scoping exercises to provide a short-list of suitable 
activity monitors. Participant-facing documents (such as information sheets and consent 
forms) were developed in collaboration with service-user research groups to ensure materials 
are understandable and describe the technology and protocol in clear language.  
Study objectives 
RADAR-MDD is a clinical study aiming to assess the utility of multi-parametric RMT in clinical 
populations with MDD.  
Specifically, RADAR-MDD aims to: 
1. Determine the usability, feasibility and acceptability of, and adherence to, RMT to 
provide real-time objective multidimensional indications of clinical state in individuals 
with MDD. 
2. Improve and refine clinical outcome measurement using RMT as a means of identifying 
current clinical state.  
3. Determine whether multi-parametric RMT collected in populations with recurrent MDD 
can provide information predictive of depressive relapse and other critical outcomes 
including anxiety, quality-of-life, and MDD remission.  
Methods 
Study Design 
RADAR-MDD is a multi-centre prospective observational cohort study in which 600 individuals 
with a recent history of MDD will be asked to download several RMT apps and use an activity 
tracker for up to 2 years of follow-up. The study involves no randomisation or intervention, and 
uses commercially available activity trackers and smartphone sensors.  
Study Population 
An estimated 100 relapses are required in order to provide sufficient power on which to test 
the predictive utility of RMT, if 10 variables were entered into the predictive model (32). With 
an approximated  annual relapse rate of 33% (a lower estimate than that provided in the Star*D 
trial; (33)), 300 participants would be required, followed-up for one year. Although there is 
evidence to suggest promising uptake to RMT protocols, the attrition rate in this length of 
follow-up is unknown, there are likely to be missing data, data are inherently “noisy”, and the 
relapse rate in our population may be lower than anticipated. We therefore aim to recruit a 
total of 600 individuals with a history of MDD across three research sites. 
The eligibility criteria for inclusion in this study are summarised in table 1. To recruit people at 
risk of relapse during the follow-up period, people with a recent history of MDD, with indication 
of a recurring trajectory will be approached to participate. No limitations have been applied 
regarding any treatment they may be receiving, although medication use and other 
psychological interventions will be monitored throughout the course of follow-up. Additionally, 
participants will be eligible to participate regardless of whether they are currently experiencing 
depression symptoms or not.  
  
 Table 1. Eligibility criteria for participation in RADAR-MDD 
Inclusion criteria Exclusion criteria 
Meet DSM-5 diagnostic criteria for diagnosis of 
non-psychotic MDD within the past 2 years. 
Recurrent MDD (a lifetime history of at least 2 
episodes of depression; (LIDAS) (34)). 
Willing and able to complete self-reported 
assessments via smartphone.  
Able to give informed consent for participation.  
Fluent in English, Spanish, Catalan or Dutch 
language 
Existing ownership of Android smartphone or 
willingness to use an Android smartphone as 
their only smartphone.  
Aged 18 or over 
Lifetime history of bipolar disorder, 
schizophrenia, MDD with psychotic features, 
schizoaffective disorders.  
Dementia 
History of moderate to severe drug or alcohol 
dependence within the last 6 months 
History of major medical disease which might 
impact upon the patient’s ability to participate in 
normal daily activities for more than 2 weeks (e.g. 
due to likely hospitalisations or other periods of 
indisposition). 
Pregnancy 
 
 
Study Procedures 
Participants will be recruited over eighteen months from three international clinical cohorts or 
research infrastructures held at King’s College London (UK); the Netherlands Study of 
Depression and Anxiety and other available patient groups at Vrije Universiteit Medisch 
Centrum (VUmc; Amsterdam, The Netherlands); and Centro de Investigacion Biomedican en 
Red (CIBER; Barcelona, Spain). The schedule of observations is available in table 2. The flow 
of participants through the study, including reasons for not participating in the study will be 
standardised across sites and documented in a flowchart (figure 1). 
Recruitment procedures will vary slightly across sites. Potentially eligible individuals will be 
identified either through existing research cohorts (in London and The Netherlands) who have 
given consent to be contacted for research purposes, or through mental health services (in 
London and Barcelona). These individuals will be contacted by a member of the on-site 
research teams and sent the study information sheet and consent from. Those who provide 
verbal consent to participate will have a more detailed conversation with the research teams, 
during which they will have an opportunity to ask questions about the study, have their 
eligibility confirmed, and arrange a suitable time for enrolment.  
Enrolment will either happen at the research centre, or at the participant’s home depending 
on the site they have been recruited from.  Participants will receive a £15/€20 for enrolling in 
the study, and £5/€10 for every three months of continued participation. Participants who take 
Table 2. Schedule of events for RADAR-MDD 
Month -1 0 1 2 3 4 5 6 7 8 9 10 11 12 … 23 24 
Visit 0 1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 2 
Study explanation (T) X                 
Informed consent (F2F)  X                
Introductory training (F2F)  X                
Baseline assessments 
Socio-demographics (R/F2F)  X                
Social Environment (R/F2F)  X                
Medical History (R/F2F)  X                
Depression History (R/F2F)  X                
Process evaluation 
Qualitative interview (F2F/T)     X         X   X 
TAM (R)     X         X   X 
PSSUQ (R)     X         X   X 
Remote Data Collection 
Wearable sensors    Continuous months 1-24  
Smartphone sensors (pRMT)   Continuous months 1-24  
ESM assessment (aRMT)*  X X X X X X X X X XX X X X X X  
Speech (aRMT)  XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX 
Mood, PHQ8 (aRMT)  XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX 
Self-esteem RSES (aRMT)  XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX 
Cognition (THINC-IT) *  X X X X X X X X X XX X X X X X  
Outcome assessment 
Relapse IDS-SR/CIDI-SF (R)  X   X   X   X   X   X 
Anxiety GAD7 (R)  X   X   X   X   X   X 
Quality-of-life WSAS (R)  X   X   X   X   X   X 
BIPQ (R)  X   X   X   X   X   X 
Remission IDS-SD/CIDI-SF (R)  X   X   X   X   X   X 
CSRI (R)  X   X   X   X   X   X 
LTE-SR (R)  X   X   X   X   X   X 
Treatment information (R)  X   X   X   X   X   X 
Alcohol use AUDIT (R)  X   X   X   X   X   X 
Clinical Interview (F2F/T)  (X)   (X)   (X)   (X)   (X)   (X) 
T: Telephone. F2F: face-to-face. R: REDCap web-based platform. pRMT: passive remote measurement app. aRMT: active remote measurement app. (X): clinical interview only 
conducted in people identified as MDD relapse cases by IDS-SR/CIDI-SF primary outcome measurement. X delivered once per month. XX delivered twice per month (every 2-weeks). 
*ESM and cognition tests are conducted once every 6 weeks.   
 
part in additional qualitative interviews at 3-month or 1-year follow-up will receive £10/€10 per 
interview. Written consent will be obtained, during the enrolment session, which will include 
collection of sociodemographic, social environment, medical history and technology use 
questionnaires, and lifetime depression history measured through the Lifetime Depression 
Assessment – Self-Report (LIDAS;(34)), alongside baseline data collection of all outcome 
measures via Research Electronic Data Capture (REDCap) software (35).  
Remote Data Collection 
RADAR-MDD is the clinical study in depression being undertaken as part of a larger body of 
work managed by the Remote Assessment of Disease and Relapse – Central Nervous System 
(RADAR-CNS; (36)) international research consortium. This includes similar clinical studies 
conducted in epilepsy and multiple sclerosis, as well as teams dedicated to patient and public 
involvement, integration into care pathways, regulation. Software engineers, data scientists 
and  software developers have developed an open-source platform to support data collection 
via wearable devices. More detailed technical information about this open-source platform and 
the sensors available for use is provided elsewhere (37). Below is a summary of the methods 
of remote data collection used in the RADAR-MDD study. 
Passive RMT (pRMT) app  
All modern smartphones comprise the sensors required for measurement in RADAR-MDD, 
however our study will only incorporate Android smartphones.  For participants who do not 
use a smartphone, we will offer to provide a suitable smartphone for them.  Participants who 
are using a non-Android smartphone will not be recruited unless they explicitly state that they 
are willing to switch to an Android smartphone as their only phone for the duration of follow-
up, and in these cases an appropriate phone will be provided. Each participant will be asked 
to install the purpose-built pRMT application. This will run in the background, requiring minimal 
input from participants, collecting data on ambient noise, ambient light, GPS location, 
keystokes (at the London site only), Bluetooth connectivity, length and duration of calls, 
number of text messages and emails and weather conditions, in addition to battery life. GPS 
location data will be obfuscated; that is, providing relative location data, not absolute 
coordinates, preventing identification of an individual’s home address or precise geographical 
location.  
Active RMT (aRMT) app  
Following extensive focus group work and user testing (31), an additional app has been 
created to administer the aRMT aspects of the study protocol. This includes validated 
questionnaires to measure depressive symptoms and self-esteem. Variability of depressive 
symptoms will be measured via the 8-item Patient Health Questionnaire (PHQ8; (38)) every 2 
weeks throughout the course of follow-up. Variation in self-esteem will be measured using the 
Rosenberg Self-Esteem Scale; RSES (39). The RSES is a widely-used 10-item self-reported 
questionnaire used to quantify self-esteem along a continuum and will be administered 
alongside the PHQ8 every 2 weeks.   
As with the PHQ8 and RSES, every 2- weeks participants will be asked to complete a speech 
task. This requires participants to say aloud, in a quiet area, some excerpts from “The North 
Wind and the Sun”, which are shown to be phonetically balanced across all three languages 
(40). These will be offered on a random schedule to prevent rehearsal and fluency and 
preserve prosodic features. In addition to this, participants will be asked to respond to the 
following question: “Can you describe something you are looking forward to this week?”.  
The aRMT app will also deliver an ESM schedule (see online supplementary material), which 
has been designed to collect brief, in-the-moment assessments relating to several of our 
domains of interest: mood, stress, sociability, activity and sleep. Participants will receive a 
series of questions intended to reflect their current state (such as “right now, I feel content”), 
with 7-point Likert scale answer options (0=Not at all, 7 = Very much). The ESM schedule 
consists of approximately 44 items, taking up to 3-minutes to complete, delivered 9 random 
times per day within 90-minute blocks starting from 08.30 and ending at 22.00 for 6 
consecutive days every 6 weeks. 
Cognitive function will also be measured using the THINC-IT® app, which has been 
specifically designed and validated to screen for cognitive dysfunction in depression (41), and 
includes assessments of elements of executive function such as memory, concentration, and 
attention. 
Wearable sensors 
The wearable device planned for use in RADAR-MDD is the FitBit Charge 2. Participants will 
be asked to wear this device for the duration of follow-up, providing ongoing data collection of 
accelerometery and heart rate, which provide information about movement, daytime activity, 
sedentary activity, physical exercise, step count, sleep efficiency, sleep latency, wake 
episodes, sleep fragmentation and post-midnight sleep start. The FitBit Charge 2 was selected 
due to its commercial availability, its competitive pricing, and the range of measurements 
available. Furthermore, it met several usability requirements highlighted by our focus groups 
and patient advisory boards, including: additional utility of a watch-face; comfort and durability; 
provided by a well-known brand (therefore reducing any potential stigma or identification as 
“research participant”); an acceptable battery life (3-5 days, requiring approximately 30 
minutes to charge fully), and an excellent app interface. In research environments, the FitBit 
has also been found to be acceptable for use by depressed samples across a relatively long 
period of follow-up (42), and has recently demonstrated good ability to accurately identify 
sleep-wake state and sleep stage cycles (43).  
Outcome Measurements 
Measurements will be taken at baseline, then every three months for the duration of follow-up 
(up to 2 years). All outcomes will be collected via Research Electronic Data Capture (REDCap) 
software (35), which sends automatic survey invitations and reminders to participants for the 
duration of the study.  
Primary Outcome 
Major Depressive Disorder relapse: The presence of MDD during follow-up will be defined as 
meeting criteria for MDD according to the Wold Health Organisation’s Composite International 
Diagnostic Interview – Short Form (CIDI-SF; (44)). The CIDI-SF has been used extensively 
on web-based platforms, and has shown excellent sensitivity and specificity to identify current 
MDD state (44). Additionally, a score of >25 on the the Inventory of Depressive 
Symptomatology – Self-Reported (IDS-SR; (45)) will be required to establish that the severity 
of the depressive episode is at least moderate. The IDS-SR is a 30-item questionnaire, widely 
used in depression trials and providing detailed information on depressive symptoms, 
including all 9 Diagnostic and Statistical Manual (DSM) domains, symptoms commonly 
associated with depression (such as irritability or pain), melancholic symptoms and atypical 
symptoms. Scores on each of the 30 items are summed to create a total score ranging from 
0-84, with the following thresholds: 0-13 (no symptoms); 14-25 (mild symptoms); 26-38 
(moderate symptoms); 39-48 (severe symptoms); 49-84 (very severe symptoms) (45). In the 
case of IDS-SR/CIDI-SF identified relapse, a confirmatory diagnostic interview will be 
conducted, to additionally confirm of relapse onset.  
Secondary Outcomes 
Anxiety will be measured via the 7-item Generalised Anxiety Disorder questionnaire; GAD7 
(46), which provides a dimensional score of anxiety symptoms which are frequently comorbid 
with depression. Quality-of-life/disability will be measured via the Work and Social Adjustment 
Scale; WSAS (47), which is a 5-item assessment of perceived social and work-related 
functional impairment used widely across a range of mental and physical disorders. Illness 
perceptions will be assessed using the Brief Illness Perceptions Questionnaire; BIPQ (48). 
The BIPQ provides an insight into the participant’s views about their underlying condition – 
including a measure of how well they see themselves coping with its symptoms and 
treatments. Alcohol use will be measured using the self-reported Alcohol Use Disorders 
Identification Test (AUDIT), which has been found to be a reliable and valid method of 
identifying at-risk and alcohol-dependent drinkers (49). MDD remission, the confirmation of 
continued remission status, or new remission status in participants who had previously 
relapsed, will be established using the IDS-SR followed by CIDI-SF. Participants scoring <14 
on the IDS-SR and who do not meet CIDI-SF criteria for MDD will be considered in a state of 
remission.  
Other measurements 
We will also seek to identify major changes in participants’ circumstances which may affect 
outcomes as well as use of RMT (such as the death of a relative or major illness), so every 3 
months we are additionally collecting information about: treatments for depression, including 
changes in antidepressants, psychological therapies and any other action the individual has 
taken to alleviate depressive symptoms, and adherence to medication. The modified Client 
Service Receipt Inventory (CSRI (50)) is a well-validated and widely used measure of health 
economic data allowing us to model costs in future analyses. Change in life circumstances will 
be assessed using the List of Threatening Experiences – Questionnaire; LTE-Q (51).  
Process Evaluation 
To ensure a system which meets participant and researcher needs, there will be continued 
monitoring of the acceptability and usability of the RADAR-CNS platform, including the app, 
assessment scheme and outcome collection platform. This will involve conducting qualitative 
interviews with a random selection of 15 participants enrolled within the first 3 months and 
thorough assessment of platform usability via self-reported questionnaires (the Post-Study 
System Usability Questionnaire (PSSUQ (52)) and the Technology Assessment Model Fast 
Form (TAM-FF; (53)). This process will be replicated in a further 15 randomly selected 
participants at the point of drop-out or at 1-year post-enrolment. At study endpoint, post-
participation qualitative interviews will be conducted in a random selection of participants who 
participated until study end-point, and those who dropped out throughout the course of follow-
up. Data obtained throughout the course of process evaluation will be used, if necessary, to 
make iterative developments to the platform software, to optimise usability of the system.  
Follow-up Procedure and Data Monitoring 
Participants will be encouraged to live their lives as normal, responding to in-app notifications 
when required and completing outcomes assessments via REDCap every 3 months for the 
duration of follow-up. The research team will be able to periodically review incoming data using 
the RADAR-CNS management portal and may contact participants if there is a loss of data 
stream from a device, to determine whether there are issues relating to functionality or user-
experience. These contacts will be recorded as evidence of feasibility and acceptability 
outcomes. In addition to the telephone call provided after the introductory training session, 
participants will receive a further call after 1-month to address any further concerns or 
questions, and brief follow-up  telephone calls will then be offered every 3 months to maintain 
engagement with participants throughout the course of the study and to remind participants of 
any upcoming outcome assessments.  
In the case of suspected depressive relapse, participants will also be contacted by research 
teams to perform clinical interview and risk assessment. In the case of a depressive relapse 
or for participants who express significant suicidal ideas, we will advise the participant to 
contact their treating physician.  If the participant is not willing to do so, the study team may, 
if sufficiently concerned, make direct contact with the treating physician without participant 
consent. Note that participants will, at recruitment, be forewarned and be asked to consent to 
this procedure.    
Study Debrief 
At the end of the follow-up period, participants will receive a maximum 60 minute “debrief” 
session, which will serve to collect end-point acceptability and usability outcomes, and include 
a qualitative interview investigating their experiences of participating for randomly selected 
participants. This will be done in person if possible, or over the phone if more convenient for 
the participant. Participants will also have an opportunity to view and discuss their own data. 
Adverse Events and Study Withdrawal 
It is not expected that participation in RADAR-MDD will increase the risk of relapse, nor of 
there being other significant risks of harm to participants. There may be several reasons for 
withdrawal from the study: 
1. Participant choosing to no longer participate; participants will be informed both in 
writing and verbally that participation is voluntary, that non-participation will not 
influence their medical care, and that they are free to withdraw from the study at any 
point without providing reasons. 
2. The research team may withdraw the participant in the event of inter-current illness, 
adverse event (AE), protocol violation, administrative or other reasons.  
3. The participant loses capacity for continued participation.   
In the case of participant self-withdrawal, all attempts will be made to follow-up with the 
participant to establish cause of withdrawal, and to collect qualitative data regarding 
experience of participation. Depressive relapse itself will not be cause for automatic 
withdrawal; unless they choose to stop, participants who are identified as experiencing a 
relapse will continue to participate until study end-point. All data, including those from 
withdrawn participants (unless they request for their data to be deleted), will be included in the 
final analysis. If a participant withdraws from the study prematurely without providing evaluable 
data, a replacement participant will be sought if resources allow.  
 
Figure 1. Participant flowchart 
  
Statistical and Analysis Plan 
Descriptive statistics for demographics, attrition rate, and number of participants using the 
remote assessment measurements without loss or damage and providing adequate data for 
the duration of the study period will be estimated. Using classification/regression approaches, 
we will investigate whether any demographics and/or other numerical information obtained 
during baseline of the study might serve as a predictor for subjects drop out/percentage of 
adequate data. Using mixed-effect models with participants as random factor, we will estimate 
whether relationships between the amount of usable data during the weeks prior to the 
outcome assessment and obtained scale’s measurements exist. 
Aggregated features obtained from biosensors, smartphones, cognitive tests and from ESM, 
as well as their changes from baseline or previous time points (delta features) will be used for 
statistical analysis. Aggregation will be done for the period of 2 weeks prior to participant’s 
evaluation with PHQ8 or longer time interval preceding 3-mothly outcome scale assessment, 
since relapse identification is done retrospectively. First, univariate approach, where each 
variable/feature will be modelled with use of mixed-effect models, with depressive relapse as 
fixed and participant as random effect, to find out which variables are influenced during the 
relapse. Demographics and other baseline characteristics will be added to the model, when 
necessary, with correction for multiple comparisons.  
Secondly, we will construct predictive models, using aggregated data obtained prior to 
assessment of relapses and their changes from previous time points to predict binary 
(relapsed or not) or continuous (when scale score is treated as continuous variable) outcomes. 
Under assumption that data are missing at random, multiple imputation will be applied for 
covariates, where missing-ness is not drastically high. Multivariate prediction model will be 
constructed and variable selection, based on, for example, LASSO L1-regularization for linear 
models, or different feature selection algorithms will be applied. Models’ performance will be 
characterized through the cross-validation, putting stress on sensitivity and specificity of 
relapse prediction model. 
Discussion 
There is substantial evidence to suggest that changes in physical activity, sleep, stress, 
prosodic features, cognitive function, mood and sociability are associated with an increased 
risk of relapse (9–13). RMT provides a new and unobtrusive way of measuring these variables, 
using smartphones and wearable technology to collect data reflective of participants’ daily 
lives and clinical symptoms. RADAR-MDD is the largest study to investigate multimodal RMT 
in a clinical cohort. If RADAR-MDD demonstrates that RMT is feasible to use in large 
populations, acceptable for participants, and provides clinically useful data, it may represent 
that start of a paradigm shift in how clinical data are collected and respective change in how 
health services are delivered (54). The RADAR-CNS platform is a device-agnostic system and 
could be applied to any diagnosis or incorporated into any study design, potentially 
transforming data collection for clinical and research purposes. 
However, to ensure translation into health services, extensive work is required to identify the 
RMT biosignatures most useful to assist in early detection of deterioration, and to understand 
the potential barriers and facilitators of large-scale uptake. There are anticipated challenges 
to this novel method of data collection. Firstly, change in health status may be a key barrier to 
long-term engagement with this study (30); an exacerbation of depressive symptoms may 
influence ongoing participation rate throughout the duration of follow-up, and participant drop-
out may represent a depressive relapse. However, there is also some evidence to suggest 
that people experiencing more severe symptoms may participate more fully, as they may be 
more motivated to  improve their understanding of their condition (55). Secondly, whilst this is 
a non-interventional study, encouraging individuals to monitor their own health and providing 
feedback on activity and sleep (via the FitBit app) may prompt people to change their 
behaviours or seek help sooner, reducing risk of relapse. There is also evidence to suggest 
that encouraging health monitoring may increase health anxiety, which in turn may contribute 
to worsening depressive symptoms (31).  
There are clear challenges to overcome, and RADAR-MDD hopes to identify as many of them 
as possible through qualitative interviews and intensive follow-up procedures and provide 
some insight into how to overcome these barriers for future implementation of RMT 
procedures. There are also important future benefits of this method of data collection. The 
data are inherently personal, and providing personalised feedback may increase individuals’ 
health awareness and facilitate self-management behaviours to improve long-term health 
outcomes (56). Furthermore, RMT may provide a solution to traditional reliance on infrequently 
measured subjective outcomes in clinical trials, which can lead to imprecision, inefficiency, 
and the need for larger sample sizes.  
RADAR-MDD is an essential step towards improving our understanding of the feasibility and 
acceptability of large-scale RMT data collection and determining the clinical utility and 
predictive ability of RMT to predict relapse in major depressive disorder.  
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